Condition
HER2-negative Early Breast Cancer
Total Trials
1
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
Treatment Research
2 treatments under study, led by Neoadjuvant Chemotherapy Upon In Vitro Ptc Drug Sensitivity Screening For Luminal Like Breast Cancer
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 1 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Phase 1/2 (1)
Trial Status
Recruiting1
Clinical Trials (1)
Research Network
Common Treatments
- Neoadjuvant Chemotherapy Upon In Vitro Ptc Drug Sensitivity Screening For Luminal Like Breast Cancer1
- Neoadjuvant Chemotherapy Upon In Vitro Ptc Drug Sensitivity Screening For Triple Negative Breast Cancer1
Active Sponsors
- Peking University People's Hospital1
Top Investigators
Peking University People's Hospital